Middle-East and Africa Colorectal Cancer Market Overview
The MEA Colorectal Cancer Market Size was valued at USD 1.90 Billion in 2023. The MEA Colorectal Cancer industry is projected to grow from USD 2.10 Billion in 2024 to USD 2.43 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.11% during the forecast period (2024 - 2032). The colon and rectum belong to our body's digestive system - together they are also known as the large bowel.Â
Colorectal cancer is cancer that starts in the colon or rectum. Colorectal cancer (CRC), also known as bowel cancer and colon cancer. The colon absorbs water and nutrients from the food and stores waste matter (stool).
Stool moves from the colon into the rectum before it leaves the body. Each year, around 5,000 Saudis are diagnosed with having cancer, such as colon cancer and breast cancer. Middle East and Africa Colorectal Cancer market is growing steadily.
In February 2024 by Exact Sciences Corporation that they are preparing to launch a new suite of tests over the coming years, including an updated version of their proven stool-based colorectal cancer screening test, Cologuard; a complementary blood-based assay and a minimal residual disease detection assay.
Guardant Health submitted Shield blood test application for premarketing approval to the FDA in May 2023.
In April 2023, Mainz Biomed disclosed its collaboration with the Instituto de Microecologia aimed at expanding ColoAlert into Spain and Portugal.
The device designed specifically for lower bowel inspection—CF-HQ1100DL/I colon videoscope has been launched by Olympus corporation. It includes anus, rectum, sigmoid colon, colon and ileocecal valve areas. This premiere would make possible broader range of products available within Olympus’ portfolio in field of colorectal cancer screening and diagnostics.
Japan's Akeda has partnered with Hutch med from Hong Kong to get commercial rights outside China for fruquintinib, which is used as a drug against colon cancer (CRC). A study combining Cotellic targeted therapy and immuno-oncologic agents for CRC treatment is being conducted by Roche scientists.
Bio-Rad Laboratories Inc.’s acquisition process of Curiosity Diagnostics Poland, based medical diagnostic innovative technology provider, ended in August 2022. The merger enabled Bio-Rad to increase its product pipeline as well as extend its presence across Middle East Africa marketplaces.
New applications have been announced by QIAGEN for QI Acuity, its ultrasensitive digital PCR (dPCR) platform, in January 2022, which is expected to revolutionize the field by utilizing “nanoplates” to process samples in two hours instead of five. In turn, it has enlarged several products offered by the firm as well as expanded its overall revenues.
Middle-East and Africa Colorectal Cancer Market Segment Insights
Middle-East and Africa Colorectal Cancer Type Insights
Middle-East and Africa Colorectal Cancer market has been segmented on the basis of type which Adenocarcinomas, Carcinoid tumors, Gastrointestinal stromal tumors (GISTs), Lymphomas, Sarcomas, and others.
Middle-East and Africa Colorectal Cancer Diagnosis Insights
On the basis of diagnosis the market is segmented into Faecal Occult Blood Test, Colonoscopy, Virtual Colonoscopy, Stool DNA test, Digital Rectal Examination, Flexible Sigmoidoscopy, Biopsy, Magnetic resonance imaging (MRI), and Others.
Middle-East and Africa Colorectal Cancer Treatment Insights
On the basis of treatment type market is segmented into Surgery, Radiation Therapy, Chemotherapy, targeted drug therapy, and others.
Middle-East and Africa Colorectal Cancer Regional Insights
Considering the Middle East and Africa Colorectal Cancer Market scenario, UAE region is believed to be the largest market for Middle East and Africa Colorectal Cancer. Moreover, Saudi Arabia market is also growing and second largest market for patient monitoring devices. On the other hand, Egypt market is expected to grow at the steady pace in the Middle East and Africa Colorectal Cancer during the forecasted period. Rest of the Middle East and Africa region is likely to have a limited but steady growth in the market.
The report for Middle East and Africa Colorectal Cancer Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance.
The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market’s segments and regions
Key Players for Middle-East and Africa Colorectal Cancer Market
Some of the key players in this market are:
- F. Hoffmann-La Roche Ltd (Switzerland)
- Amgen Inc. (US)
- Novartis AG(Switzerland)
- Beckman Coulter Inc. (US)
- Debiopharm Group (Switzerland)
- AbbVie Inc. (US)
- Abbott (US)
- Bayer AG (Germany)
Study Objectives of Middle-East and Africa Colorectal Cancer Market
- To provide detailed analysis of the market structure along with forecast for the next 5 years of the various segments and sub-segments of the Middle East and Africa Colorectal Cancer market
- To provide insights about factors affecting the market growth
- To analyse the Middle East and Africa Colorectal Cancer market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to two main geographies and their countries- Middle East & Africa.
- To provide country level analysis of the market with respect to the current market size and future prospective
- To provide country level analysis of the market for segments by type, by diagnosis, by treatment type and its sub-segments.
- To provide overview of key players and their strategic profiling in the market, comprehensively analysing their core competencies, and drawing a competitive landscape for the market
- To track and analyse competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Middle East and Africa Colorectal Cancer market.
Intended Audience
- Middle-East and Africa Colorectal Cancer Equipment manufacturers
- Middle-East and Africa Colorectal Cancer Equipment Suppliers
- Government and Independent Regulatory Authorities
- Research and Development (R&D) Companies
- Independent Research Laboratories
- Market Research and Consulting Service Providers
- Medical Research Laboratories
|
Attribute/Metric
|
Details
|
|
  Market Size 2032
|
  USD 2.43 Billion
|
|
  CAGR
|
  6.11% (2024 -2032)
|
|
  Base Year
|
  2023
|
|
  Forecast Period
|
 2024 -2032
|
|
  Historical Data
|
  2020
|
|
  Forecast Units
|
  Value (USD Billion)
|
|
  Report Coverage
|
  Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
  Segments Covered
|
  Type, Diagnosis and Treatment Type
|
|
  Geographies Covered
|
  UAE, Saudi Arabia, Egypt
|
|
  Key Vendors
|
  F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (US), Novartis AG(Switzerland), Abbott (US), Beckman Coulter Inc. (US), Debiopharm Group (Switzerland), AbbVie Inc. (US), Bayer AG (Germany)
|
|
  Key Market Opportunities
|
  Joint ventures, strategic alliances, mergers and acquisitions, new product developments
|
|
  Key Market Drivers
|
  technological advancement, macro economical and governing factors
|
